Instrument Inactif

Autres langues Vifor Pharma London S.E.

Actions

0RPD

CH0364749348

Produits pharmaceutiques

Autres langues

22/07/24	EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung
19/04/24	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments
02/05/23	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
14/12/22	Court Cancels Public Shares of Vifor Pharma after Merger with CSL
14/12/22	Vifor-Aktien werden am 23. Dezember dekotiert
14/12/22	Cancellation of remaining publicly held registered shares of Vifor Pharma AG
28/11/22	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
25/11/22	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously
03/11/22	Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand
20/10/22	Approval of extension of exemptions from SIX disclosure and publicity obligations
17/10/22	Australia's CSL raises annual profit forecast on Swiss acquisition
12/10/22	Global markets live: Darktrace, Intel, Twitter, Meta, Uber...
12/10/22	Bolsa de Madrid: El peso de las palabras
12/10/22	Vifor erhält Genehmigung für Dekotierung von der Schweizer Börse
12/10/22	Vifor Pharma Gets Approval To Delist From Swiss Bourse
12/10/22	Approval of delisting of Vifor Pharma AG's registered shares
06/10/22	Kapruvia® (Difelikefalin) jetzt in Deutschland für Hämodialysepatient:innen mit CKD-assoziiertem Pruritus erhältlich
04/10/22	Isabelle Welton nuova presidente del cda della NZZ
28/09/22	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease
27/09/22	Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis
08/09/22	Schweizer Unternehmen dürften auch aktuelle Krise gut überstehen
05/09/22	ÜBERBLICK/Anstehende Indexänderungen per 19. September
02/09/22	ÜBERBLICK/Anstehende Indexänderungen zum 19. September
25/08/22	Fitch Pulls Vifor Pharma's Rating After CSL Takeover
23/08/22	Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU